Cushing’s Awareness Challenge Countdown…

One-day-to-go

What’s this about? More info here.

Cushing’s Awareness Challenge Countdown…

The Countdown Begins…

Only 2 days (counting today) until the Cushing’s Awareness Challenge begins.  At night, when I’m supposed to be sleeping, ideas for posts keep swarming through my head.  Sometimes, they form into fully-written posts.  Then, when I wake up, the posts are gone.

I plan to follow the suggestions to some extent and have a few ideas of my own.  Over the years, I’ve posted lots on several blogs but I don’t know if I can get 30 days of Cushing’s stuff together!

At the moment, there are 23 participants in this challenge and growing.  Please follow their blogs.  The list is here and is constantly updated as new URLs come in.

If you want to join us, its not too late.  Directions and suggestions for posts can be found here: http://cushie-blogger.blogspot.com/2012/03/cushing-awareness-challenge.html

If you have ideas for what you’d like to read about (Cushing’s related, of course), please feel free to put it in the comments area.

 

 

 

A classification tree approach for pituitary adenomas

Summary

It is difficult to evaluate the recurrence and progression potential of pituitary adenomas at presentation. The World Health Organization classification of endocrine tumors suggests that invasion of the surrounding structures, size at presentation, an elevated mitotic index, a Ki-67 labeling index higher than 3%, and extensive p53 expression are indicators of aggressive behavior.

Nevertheless, Ki-67 and p53 labeling index evaluation is subject to interobserver variability, and their cutoff values are controversial. In the present study, the prognostic value of Ki-67 and p53 protein labeling indices and their correlation with clinical and radiologic parameters were evaluated using digital image analysis in a series of 166 pituitary adenomas in patients having undergone a follow-up of at least 6 years to evaluate the impact on the recurrence and progression potential of pituitary adenomas.

The data were analyzed using the receiver operating characteristic curve and classification and regression tree analysis. The results showed that, in the unstratified data set, the commonly used threshold of the Ki-67 index of 3% has a high specificity (89.5%) but a low sensitivity (53.8%).

Unsatisfactory performance results were obtained by performing receiver operating characteristic curve analysis on the p53 labeling index. On the contrary, the classification and regression tree analysis–derived tree demonstrated that each pituitary adenoma subtype has specific prognostic factors.

Specifically, the Ki-67 labeling index is a useful prognostic factor in nonfunctioning, adrenocorticotropin, and prolactin adenomas, but with different thresholds. In conclusion, our study emphasizes that the term pituitary adenomas includes different types of tumors, each one having specific prognostic factors.

Access the entire article here: http://www.humanpathol.com/article/PIIS0046817711004965/abstract?rss=yes

PharmaForm announces commercial manufacturing contract for Corcept’s Korlym™

PharmaForm announced  that Corcept Therapeutics Inc. has chosen PharmaForm as their primary commercial manufacturer for their newly approved drug product, Korlym™. The U.S. Food and Drug Administration approved Corcept’s Korlym™ on February 17th, 2012 for patients with endogenous Cushing’s syndrome.

PharmaForm, a full-service contract provider of development and manufacturing for the pharmaceutical and biotech industry, has worked with Corcept for several years as a contract provider for services in the development, optimization and validation of the manufacturing process for Corcept’s Korlym™.

Read the entire article here: http://www.marketwatch.com/story/pharmaform-announces-commercial-manufacturing-contract-for-corcepts-korlym-2012-03-26